NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Precigen, Inc. PGEN
15 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$9.7M
▲ 146.7% vs FY2024
EPS · FY25
$-1.37
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-843.6%
Net margin · FY25
-2588.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 9.7M
Revenue, FY2025 · full 15-year series below
Revenue
Net income
The company lost 2588 cents on every revenue dollar this year.
Per share
USD -1.37
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-843.6%
Return on equity, FY2025
ROE
Operating margin-1141.1%
Net margin-2588.2%
Return on assets-166.7%
Each USD of equity lost 844 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−21.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−28.9%
−21.3%
−25.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.35B
Shares outstanding, FY2025
Change, 5 years+88.6%
Change, 10 years+203.4%
The share count grew 89% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 155.5M
total assets, end of FY2025
Total assetsUSD 155.5M
EquityUSD 20.9M
CashUSD 30.2M
Gross debtUSD 93.2M
Net debtUSD 62.9M
Current ratio3.09×
Net debt stands at 301% of equity.
History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.1
0.2
0.2
0.2
0.2
0.1
0.0
0.0
0.0
Operating income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.2
−0.4
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
EBITDA $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.4
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
Income tax $B
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
0.0
−0.0
0.0
0.0
0.0
Net income $B
−0.3
−0.1
−0.1
0.0
−0.1
−0.2
−0.3
−0.5
−0.1
−0.2
−0.1
−0.1
−0.0
−0.1
−0.1
EPS, diluted $
−1.37
−0.47
−0.39
0.14
−0.47
−1.02
−2.09
−3.93
−0.98
−1.58
−0.76
−0.83
−1.40
−18.77
−18.92
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−843.6
−160.8
−78.4
24.2
−105.6
−245.6
−148.3
−113.6
−21.4
−29.8
−15.7
−21.8
−172.6
·
·
Shares out B
0.35
0.29
0.25
0.21
0.21
0.19
0.16
0.16
0.12
0.12
0.12
0.10
0.10
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
43 of 43
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed